Drug Eluting Stent News and Research

RSS

A drug-eluting stent (DES) is a coronary stent (a scaffold) placed into narrowed, diseased coronary arteries that slowly releases a drug to block cell proliferation. This prevents fibrosis that, together with clots (thrombus), could otherwise block the stented artery, a process called restenosis.

HCRI completes enrollment in dual antiplatelet therapy clinical trial

The Harvard Clinical Research Institute (HCRI) announced today that the enrollment phase of the DAPT Study has been successfully completed. The DAPT Study is a four-year clinical trial investigating the duration of dual antiplatelet therapy (DAPT, the combination of aspirin and a thienopyridine/antiplatelet medication to reduce the risk of blood clots) following drug-eluting stent implantations.

27 Sep 2011

Xience V stent performs well in patients with primary PCI for ST elevation myocardial infarction

The second generation drug-eluting stent Xience V performs well in patients having primary PCI for ST elevation myocardial infarction, and has a better safety profile than that of bare metal stents, according to results of the EXAMINATION trial.

30 Aug 2011

Everolimus-eluting stent and SES are equally effective for PCI patients

The second generation drug-eluting stent, everolimus-eluting stent (EES), has consistently demonstrated superior clinical outcomes in randomised controlled trials over the first generation drug-eluting stent, paclitaxel-eluting stent.

29 Aug 2011

Abbott initiates ABSORB BVS device clinical trial in coronary artery disease

Abbott announced today that the first patient in Japan has been treated with the ABSORB bioresorbable vascular scaffold (BVS) as part of the ABSORB EXTEND clinical trial.

18 Aug 2011

Resolute drug-eluting stent superior to Taxus DES for coronary artery disease

The Resolute drug-eluting stent (DES) from Medtronic, Inc., showed superiority to Boston Scientific Corp.'s Taxus DES on the primary endpoint of the RESOLUTE Japan clinical study: in-stent late lumen loss at eight months.

26 Jul 2011

BIOTRONIK begins comparative study of ORSIRO stent with Abbott's XIENCE PRIME stent

BIOTRONIK announced today the start of an international study comparing the company's ORSIRO sirolimus-eluting coronary stent with Abbott Laboratory's XIENCE PRIME everolimus-eluting coronary stent. The first implantations in the study, called BIOFLOW-II, took place in Europe last week.

14 Jul 2011

Positive results for unprotected left main coronary artery PCI with drug-eluting stents

Patients with normal left ventricular function who undergo elective unprotected left main coronary artery (ULMCA) percutaneous coronary intervention (PCI) with drug-eluting stents (DES) had favorable outcomes according to new research. Results of the multicenter, retrospective study are reported in the June issue of Catheterization and Cardiovascular Interventions, a journal published by Wiley-Blackwell on behalf of The Society for Cardiovascular Angiography and Interventions (SCAI).

22 Jun 2011

The Lancet publishes final 3-year data from landmark HORIZONS-AMI clinical trial

Data from the landmark HORIZONS-AMI clinical trial demonstrated that the administration of the anticoagulant medication bivalirudin enhanced survival compared to the use of heparin plus a glycoprotein (GP) IIb/IIIa inhibitor in heart attack patients undergoing angioplasty after 3 years. Use of a drug-eluting stent was also shown to be more effective than a bare-metal stent, with equivalent safety.

14 Jun 2011

FDA approves Abbott's XIENCE nano stent for treatment of coronary artery disease in small vessels

Abbott today announced it has received U.S. Food and Drug Administration approval for the XIENCE nano Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease in small vessels.

25 May 2011

Elixir DESyne Drug Eluting Coronary Stent System granted CE Mark approval

Elixir Medical Corporation, a developer of product platforms combining state-of-the-art medical devices with advanced pharmaceuticals, announced that it has received CE Mark for its DESyne Drug Eluting Coronary Stent System for the treatment of coronary artery disease.

23 May 2011

Global clinical program demonstrates safety of Medtronic Resolute drug-eluting stent

A pooled analysis of the global RESOLUTE clinical program presented today during a late-breaking clinical trials session at EuroPCR demonstrated the strong safety record of the Resolute drug-eluting stent (DES) from Medtronic, Inc., across a wide variety of patient and lesion types.

From Medtronic 21 May 2011

Clinical data of Medtronic's Resolute drug-eluting stent in diabetes presented at EuroPCR meeting

For patients with both heart disease and diabetes who took part in a pooled series of rigorous clinical trials, the Resolute drug-eluting stent from Medtronic, Inc., provided remarkably safe and effective outcomes, according to the results of several studies presented today at EuroPCR, a major international meeting for cardiac and vascular specialists.

From Medtronic 18 May 2011

CHOP forms first startup firm to develop treatments for peripheral artery disease

Building on its extensive laboratory research using magnetically guided nanoparticles to deliver drugs to diseased blood vessels, The Children's Hospital of Philadelphia has just spun off its first startup company, Vascular Magnetics, Inc.

10 May 2011

Boston Scientific launches ION Paclitaxel-Eluting Platinum Chromium Coronary Stent System

Boston Scientific Corporation today announced U.S. Food and Drug Administration (FDA) approval and launch of the ION™ Paclitaxel-Eluting Platinum Chromium Coronary Stent System, the Company's third-generation drug-eluting stent technology.

25 Apr 2011

GRAVITAS study shows no benefit of double-dose compared with standard-dose clopidogrel

An international consortium of scientists, including major contributions from the Montreal Heart Institute, demonstrates that the "one-size fits all" strategy of uniformly doubling the dose of an antiplatelet drug, clopidogrel, for patients with high on-treatment platelet reactivity does not reduce the incidence on death, heart attacks and stent thrombosis after percutaneous coronary intervention.

16 Apr 2011

Positive outcomes from Medtronic's Resolute drug-eluting stent against coronary artery disease

Results of two major clinical studies presented at ACC.11 - the 60th Annual Scientific Session & Expo of the American College of Cardiology - demonstrate that the Resolute drug-eluting stent from Medtronic, Inc., provides a positive and persistent treatment effect for a wide variety of patients with coronary artery disease.

5 Apr 2011

Abbott's XIENCE V Coronary Stent System data presented at ACC meeting

A pooled analysis of the SPIRIT II, III, IV and COMPARE trials presented today further reinforces the positive clinical performance of Abbott's market-leading XIENCE V Everolimus Eluting Coronary Stent System.

4 Apr 2011

BSX presents ION and TAXUS Stent trial data against coronary artery disease at ACC meeting

Boston Scientific Corporation today announced results from a pooled patient-level analysis of its PERSEUS and TAXUS ATLAS clinical trial data, demonstrating differences in safety and efficacy outcomes favoring the next-generation ION Platinum Chromium Paclitaxel-Eluting Stent System compared to the currently available TAXUS Liberte Paclitaxel-Eluting Stent System.

4 Apr 2011

Positive results from Abbott's ABSORB device trial in coronary artery disease

Abbott today announced positive one-year results from 101 patients enrolled in the second phase of the ABSORB trial evaluating the world's first drug eluting Bioresorbable Vascular Scaffold for the treatment of coronary artery disease.

4 Apr 2011

Medtronic's Resolute drug-eluting stent pivotal U.S. data to be presented at ACC.11

Medtronic, Inc., today announced the imminent release of the pivotal U.S. data on its Resolute drug-eluting stent at ACC.11, the 60th Annual Scientific Session & Expo of the American College of Cardiology, which takes place April 2-5 in New Orleans.

29 Mar 2011

Drug Eluting Stent News and Research

Further Reading

HCRI completes enrollment in dual antiplatelet therapy clinical trial

Xience V stent performs well in patients with primary PCI for ST elevation myocardial infarction

Everolimus-eluting stent and SES are equally effective for PCI patients

Abbott initiates ABSORB BVS device clinical trial in coronary artery disease

Resolute drug-eluting stent superior to Taxus DES for coronary artery disease

BIOTRONIK begins comparative study of ORSIRO stent with Abbott's XIENCE PRIME stent

Positive results for unprotected left main coronary artery PCI with drug-eluting stents

The Lancet publishes final 3-year data from landmark HORIZONS-AMI clinical trial

FDA approves Abbott's XIENCE nano stent for treatment of coronary artery disease in small vessels

Elixir DESyne Drug Eluting Coronary Stent System granted CE Mark approval

Global clinical program demonstrates safety of Medtronic Resolute drug-eluting stent

Clinical data of Medtronic's Resolute drug-eluting stent in diabetes presented at EuroPCR meeting

CHOP forms first startup firm to develop treatments for peripheral artery disease

Boston Scientific launches ION Paclitaxel-Eluting Platinum Chromium Coronary Stent System

GRAVITAS study shows no benefit of double-dose compared with standard-dose clopidogrel

Positive outcomes from Medtronic's Resolute drug-eluting stent against coronary artery disease

Abbott's XIENCE V Coronary Stent System data presented at ACC meeting

BSX presents ION and TAXUS Stent trial data against coronary artery disease at ACC meeting

Positive results from Abbott's ABSORB device trial in coronary artery disease

Medtronic's Resolute drug-eluting stent pivotal U.S. data to be presented at ACC.11

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News